<DOC>
	<DOCNO>NCT00362505</DOCNO>
	<brief_summary>The purpose study determine safety efficacy clevudine 10 mg qd 24 week completion 24-week treatment clevudine 30 mg qd 12 week follow-up period</brief_summary>
	<brief_title>Safety Antiviral Activity Clevudine Patients Who Have Completed L-FMAU-301 L-FMAU-302 Trials</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>1 . Patient 18 60 , inclusive 2 . Patients complete LFMAU301 LFMAU302 clinical trial . 3 . Patient HBsAg positive week 48 LFMAU301 LFMAU302 . 4 . Patient bilirubin level less 2.0 mg/dL , prothrombin time le 1.7 ( INR ) , serum albumin level least 3.5 g/dL week 48 LFMAU301 LFMAU302 . 5 . Women childbearing potential must negative serum ( βHCG ) pregnancy test screening . 6 . Patient able give write informed consent prior study start comply study requirement . 1 . Patients HBV DNA &lt; 4,700 copies/mL , ALT normalization consecutive e seroconversion week 40 48 LFMAU301 2 . Patients HBV DNA &lt; 4,700 copies/mL ALT normalization LFMAU302 3 . Patient currently receive antiviral , immunomodulatory corticosteroid therapy . 4 . Patients previously treat αinterferon , lamivudine , lobucavir , adefovir investigational nucleoside HBV infection . 5 . Patient history ascites , variceal hemorrhage hepatic encephalopathy . 6 . Patient coinfected HCV , HDV HIV . 7 . Patient clinical evidence liver mass hepatocellular carcinoma αFetoprotein &gt; 50 ng/mL 8 . Patient pregnant breastfeeding . 9 . Patient unwilling use `` effective '' method contraception study 3 month use study drug cease . For male , condom use . Females must surgically sterile ( via hysterectomy bilateral tubal ligation ) postmenopausal use least medically acceptable barrier method contraception ( i.e . IUD , barrier method spermicide abstinence ) 10 . Patient clinically relevant history abuse alcohol drug . 11 . Patient significant gastrointestinal , renal , hepatic ( decompensated ) , bronchopulmonary , biliary disease exclude asymptomic GB stone , neurological , cardiovascular , oncologic allergic disease . The patient benign tumor except liver mass , exclude judge investigator continuation study would interfere tumor . 12 . Patient creatinine clearance le 60mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) / ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ] 13.Patient investigator consider suitable study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
</DOC>